“We’re experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon’s Michael Manolakis. Read More
Ozempic isn’t alone. A whole class of ‘revolutionary’ weight-loss drugs is on the market—but only for the wealthy
